Cryoport, Inc. (NASDAQ:CYRX – Free Report) – Stock analysts at B. Riley decreased their Q3 2023 earnings estimates for shares of Cryoport in a research report issued to clients and investors on Monday, October 30th. B. Riley analyst Y. Zhi now forecasts that the company will post earnings of ($0.34) per share for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Cryoport’s current full-year earnings is ($1.11) per share. B. Riley also issued estimates for Cryoport’s Q4 2023 earnings at ($0.35) EPS and FY2023 earnings at ($1.26) EPS.
A number of other research firms also recently commented on CYRX. Morgan Stanley started coverage on shares of Cryoport in a research report on Thursday, August 17th. They issued an “equal weight” rating and a $16.00 target price for the company. Needham & Company LLC cut their price objective on shares of Cryoport from $30.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, August 10th. Stephens downgraded shares of Cryoport from an “overweight” rating to an “equal weight” rating and set a $15.00 price objective for the company. in a research report on Thursday, August 10th. SVB Securities downgraded shares of Cryoport from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $30.00 to $10.00 in a research report on Thursday, July 13th. Finally, UBS Group downgraded shares of Cryoport from a “buy” rating to a “neutral” rating and cut their price objective for the company from $28.00 to $17.00 in a research report on Tuesday, July 18th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Cryoport presently has a consensus rating of “Hold” and an average price target of $20.78.
Cryoport Trading Up 1.5 %
NASDAQ:CYRX opened at $9.66 on Thursday. The company has a current ratio of 14.54, a quick ratio of 13.82 and a debt-to-equity ratio of 0.78. Cryoport has a 12 month low of $9.00 and a 12 month high of $27.47. The company has a market cap of $472.18 million, a PE ratio of -9.96 and a beta of 1.27. The company has a 50 day simple moving average of $12.65 and a two-hundred day simple moving average of $16.31.
Cryoport (NASDAQ:CYRX – Get Free Report) last posted its earnings results on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.17). Cryoport had a negative return on equity of 7.23% and a negative net margin of 16.07%. The company had revenue of $57.02 million during the quarter, compared to the consensus estimate of $56.94 million.
Institutional Trading of Cryoport
Hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its position in shares of Cryoport by 228.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock valued at $36,000 after buying an additional 1,433 shares in the last quarter. Quarry LP purchased a new stake in shares of Cryoport during the 2nd quarter valued at about $40,000. State of Wyoming grew its holdings in Cryoport by 42.7% during the 4th quarter. State of Wyoming now owns 3,026 shares of the company’s stock valued at $53,000 after purchasing an additional 905 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Cryoport by 54.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,484 shares of the company’s stock valued at $60,000 after purchasing an additional 878 shares during the last quarter. Finally, FMR LLC grew its holdings in Cryoport by 34.1% during the 1st quarter. FMR LLC now owns 2,935 shares of the company’s stock valued at $70,000 after purchasing an additional 747 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Cryoport
In other Cryoport news, insider Jerrell Shelton sold 26,875 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $14.27, for a total value of $383,506.25. Following the sale, the insider now owns 632,424 shares in the company, valued at approximately $9,024,690.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.50% of the stock is owned by corporate insiders.
Cryoport Company Profile
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
- Five stocks we like better than Cryoport
- EV Stocks and How to Profit from Them
- A bullish storm is brewing for cloud stocks
- How to Invest in the Best Canadian Stocks
- Is Extreme Networks’ forecast a sign of industry woes?
- What is the Dow Jones Industrial Average (DJIA)?
- Profits come after ignorance Is highest: A PayPal story
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.